- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02028442
Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients (EVOLVE)
A Clinical Study Of Enadenotucirev Administered by Sub-Acute Fractionated Intravenous Injection: Dose Escalation in Metastatic Epithelial Solid Tumours and Randomised Controlled Trial in Metastatic Colorectal Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Bruxelles, Belgium, B-1200
- Cliniques Universitaires St Luc
-
Ghent, Belgium, 9000
- Ghent University Hospital
-
-
Antwerp
-
Wilrijk, Antwerp, Belgium, B-2610
- GZA Ziekenhuizen campus Sint-Augustinus
-
-
-
-
-
Barcelona, Spain, 08970
- Institut Catala d Oncologica
-
Madrid, Spain, 28050
- START - Hospital Universitario Madrid Sanchinarrio
-
Seville, Spain, 41013
- Hospital Universitario Virgen del Rocio (HUVR)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must provide written informed consent
- Age ≥ 18 years and the patient must be at least the legal age limit to be able to give consent within the jurisdiction the study is taking place.
- ECOG performance status 0 or 1
- Predicted life expectancy of 3 months or more
- Ability to comply with study procedures in the Investigator's opinion
- Recovered to Grade 1 from the effects (excluding alopecia) of any prior therapy for their malignancies
Adequate renal function
- Creatinine ≤ 1.5 mg/dL or calculated creatinine clearance using the Cockcroft-Gault formula ≥ 60 mL/min, or measured creatinine clearance ≥ 60 mL/min, Haematuria: dipstick ≤ 2+
- Proteinuria: dipstick ≤ 2+
Adequate hepatic function
- Serum bilirubin < 1.5 mg/dL
- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3x upper limit of normal (ULN)
Adequate bone marrow function:
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- Platelets ≥ 100 x 109/L
- Haemoglobin ≥ 100 g/L for UCC and ≥ 90 g/L for other cancers
- Adequate coagulation tests: international normalised ratio (INR) ≤ 1.5 x ULN
- For females of childbearing potential (defined as <2 years after last menstruation or not surgically sterile), a negative serum pregnancy test must be documented within 14 days prior to first administration of study treatment
- For women who are not postmenopausal (24 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two adequate methods of contraception, during the treatment period and for at least 3 months after the last dose of study drug
- For men: agreement to use a barrier method of contraception during the treatment period and for at least 6 months after the last dose of study drug
- At least 3 weeks since any dose of IV systemic chemotherapy and at least two weeks since any oral dose of capecitabine at the time of first administration of ColoAd1.
Phase I Specific Inclusion Criteria:
Dose Escalation Stage only (except Repeat Cycle Cohort):
- Solid tumour of epithelial origin not responding to standard therapy or for whom no standard treatment exists
Dose Expansion Stage Single Cycle and Dose Escalation Stage Repeat Cycle Cohort:
- mCRC not responding to standard therapy
- ≤ 3 prior lines of systemic therapy for advanced disease OR ≤ 4 prior lines of systemic therapy for advanced disease if one of the 4 lines was an anti EGFR therapy given as a single agent or combined to a previously administered chemotherapy regimen Phase Ib:mCRC not responding to standard therapy
- no more than 3 prior lines of systemic therapy for advanced disease OR no more than 4 prior lines of systemic therapy for advanced disease if one of the 4 lines was an anti EGFR therapy given as a single agent or combined to a previously administered chemotherapy regimen
- Advanced or metastatic UCC, who have received a maximum of one chemotherapy-containing regimen and a maximum of one other systemic treatment with biologic agents only.
Phase II Specific Inclusion Criteria:
- mCRC
- Have received 3 - 4 months of first line chemotherapy with either FOLFOX, FOLFIRI or CAPOX, with or without bevacizumab
- At least one measurable lesion according to RECIST 1.1 criteria
- Documented partial response or stable disease
- Eligible to receive chemotherapy with FOLFOX or CAPOX after a short chemotherapy interruption (3 to 4 weeks)
Exclusion Criteria for all Patients:
- Pregnant or breast feeding females;
- Known history or evidence of significant immunodeficiency due to underlying illness (e.g. human immunodeficiency virus [HIV]/acquired immunodeficiency syndrome [AIDS]) and/or medication (e.g. systemic corticosteroids, or other immunosuppressive medications including cyclosporine, azathioprine, interferons, within the past 4 weeks)
- Splenectomy
- Prior allogeneic or autologous bone marrow or organ transplantation
- Active infections requiring antibiotics, physician monitoring, or recurrent fevers >38.0 degrees centigrade associated with a clinical diagnosis of active infection
- Active viral disease or known positive serology for HIV, hepatitis B or hepatitis C;
- Use of the following anti-viral agents: ribavirin, adefovir, lamivudine or cidofovir within 7 days prior to day 1; or pegylated interferon (PEG-IFN) (within 14 days prior to first administration of ColoAd1)
- Administration of an investigational drug within 28 days prior to first dose of ColoAd1
- Major surgery within 4 weeks or radiotherapy within 3 weeks prior to first dose of ColoAd1
- Another primary malignancy within the past 3 years (except for non melanoma skin cancer or cervical cancer in situ)
- Central nervous system (CNS) metastasis that is symptomatic and/or requires treatment
- Any condition or illness that, in the opinion of the Investigator or the medical monitor, would compromise patient safety or interfere with the evaluation of the safety of the drug
- Known allergy to treatment medication or its excipients
- Any other medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent
Phase II Specific Exclusion Criteria:
- Progression on first line therapy
- A complete response on first line therapy
- Use of first line therapy for longer than 4 months
- Use of any first line treatment with a chemotherapy regimen other than FOLFOX, FOLFIRI or CAPOX (each with or without bevacizumab)
- More than 6 weeks since the last administration of 5 FU, capecitabine, oxaliplatin or irinotecan
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Enadenotucirev
|
Oncolytic virus
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1 - Maximum Tolerated Dose
Time Frame: Up to Day 22
|
- Maximum tolerated dose (MTD) / maximum feasible dose (MFD) of enadenotucirev when administered by sub-acute fractionated IV injection (phase I Dose Escalation) and recommended dose for phase II.
|
Up to Day 22
|
Phase 1b - Selection of suitable schedule for repeat cycle IV administration
Time Frame: Up to Day 134
|
Open label assessment of 2 repeat cycle schedules, with expansion cohort at the MTD or MFD with best repeat cycle schedule in advanced/metastatic UBC patients.
|
Up to Day 134
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ColoAd1-1001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Cancer
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Hutchison Medipharma LimitedActive, not recruitingMetastatic Colorectal Cancer | Metastatic Colon CancerUnited States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
Dana-Farber Cancer InstituteAmerican Cancer Society, Inc.Not yet recruitingMetastatic Colorectal Cancer | Colorectal Cancer | Metastatic Colon CancerUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Oncology
-
Symphogen A/STerminatedCarcinoma | Metastatic Colorectal Cancer | Colorectal Cancer MetastaticUnited States, Spain, Germany, Italy
Clinical Trials on Enadenotucirev
-
PsiOxus Therapeutics LtdCompletedRecurrent Platinum Resistant Ovarian CancerUnited Kingdom, Spain
-
University of OxfordCancer Research UK; Akamis BioCompletedLocally Advanced Rectal CancerUnited Kingdom
-
Akamis BioBristol-Myers Squibb; Syneos HealthCompletedColorectal Cancer | Squamous Cell Carcinoma of the Head and Neck | Epithelial TumorUnited States